Literature DB >> 12528316

INGN-241. Introgen.

Rahul Gopalkrishnan1.   

Abstract

Introgen, under license from Corixa (formerly GenQuest), is developing INGN-241, a gene therapy based on the mda-7 gene in combination with the company's adenoviral delivery system, for the potential treatment of cancer. A phase I trial for the treatment of solid tumors was initiated at the end of November 2000.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12528316

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  3 in total

1.  Interleukin-24 and its receptors.

Authors:  Mai Wang; Peng Liang
Journal:  Immunology       Date:  2005-02       Impact factor: 7.397

2.  Adenoviral endoplasmic reticulum-targeted mda-7/interleukin-24 vector enhances human cancer cell killing.

Authors:  Abujiang Pataer; Wenxian Hu; Lu Xiaolin; Sunil Chada; Jack A Roth; Kelly K Hunt; Stephen G Swisher
Journal:  Mol Cancer Ther       Date:  2008-08       Impact factor: 6.261

Review 3.  mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine.

Authors:  Pankaj Gupta; Zao-zhong Su; Irina V Lebedeva; Devanand Sarkar; Moira Sauane; Luni Emdad; Michael A Bachelor; Steven Grant; David T Curiel; Paul Dent; Paul B Fisher
Journal:  Pharmacol Ther       Date:  2006-02-07       Impact factor: 12.310
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.